Adrenocortical carcinoma is a rare, highly malignant neoplasmwith an incidence of 2 cases per 1 million population per yearworldwide, representing 0.2% of all cases of cancer. Severaltreatment strategies in patients with advanced disease haveresulted in temporary or partial tumor regression, yet veryfew patients attain long-term survival. Assessing the effectivenessof most published treatment protocols has been difficult, sincemost series have been limited by the inclusion of relativelyfew subjects, with tumors at various stages and grades. Severaldrug regimens have been used, and multiple treatments have beenadministered in various sequences. In addition, the . . . [Full Text of this Article]
Source Information
From the Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical Center, Ann Arbor.
Related Letters:
Adjuvant Mitotane in Adrenocortical Carcinoma
Bertherat J., Coste J., Bertagna X., Dickstein G., Shechner C., Nativ O., Lee J. E., Machens A., Dralle H., Terzolo M., Fassnacht M., Berruti A.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:1256-1259, Sep 20, 2007.
Correspondence
This article has been cited by other articles:
Bertherat, J., Coste, J., Bertagna, X., Dickstein, G., Shechner, C., Nativ, O., Lee, J. E., Machens, A., Dralle, H., Terzolo, M., Fassnacht, M., Berruti, A.
(2007). Adjuvant Mitotane in Adrenocortical Carcinoma. NEJM
357: 1256-1259
[Full Text]
(2007). Adjuvant Therapy for Adrenal Cancer. JWatch Oncology and Hematology
2007: 1-1
[Full Text]
Previous
